The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

(RTTNews) - Drug major Merck & Co., Inc. (MRK) Friday announced positive results of Phase 3 trials with its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in various cancers. In the Phase 3 KEYNOTE-756 ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda ® (pembrolizumab) in combination with other therapies to treat multiple myeloma, ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...

CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...

Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima, in patients with certain types ...

Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy achieved positive results as a treatment ...

A clinical trial has started to evaluate the investigational drug MK-1084 and Keytruda among some patients with metastatic non-small cell lung cancer. A phase 3 clinical trial has been launched among ...